Regulatory Affairs Manager (gn) Design Control
Formycon is an international leading, independent developer of high-quality biopharmaceutical medicines, especially biosimilars. With an experienced team comprised of around 240 highly skilled profess...
Energieversorgung und Infrastruktur regional
Asset Manager (m/w/d)
Bayern, Landsberg am Lech
Über unseren Auftraggeber:
Energieversorgung und Infrastruktur regional
Die Stadtwerke Landsberg, die als Kommunalunternehmen zu 100 % der Stadt Landsber...
Vollzeit
Landsberg am Lech
Stadtwerke Landsberg über Dr. Heimeier Executive Search GmbH
IT Business Partner (gn)
Formycon is an international leading, independent developer of high-quality biopharmaceutical medicines, especially biosimilars. With an experienced team comprised of around 240 highly skilled professionals, the company is ...
We are the Klinikum rechts der Isar (MRI), Hospital of Munich Technical University (TUM), and a reliable employer of around 6,600 people. Being a university hospital, we not only look after our patients but, based on our motto “Knowledge Creates C...
Information Security Manager (gn)
Work experience
Senior, very experienced
IT
Fulltime
Formycon is an international leading, independent developer of high-quality biopharmaceutical medicines, especially biosimilars. With an experienced ...
Head of Regulatory Affairs CMC Drug Product (gn)
Manager First Level
Medicine, Pharmacy, Laboratory
Quality Management, Quality Assurance
Formycon is an international leading, independent developer of high-quality biopharmaceutical medicin...
CatalYm GmbH is a clinical-stage biotechnology company dedicated to advancing cancer treatment through pioneering Visugromab, a recombinant antibody targeting the immunosuppressive cytokine GDF-15. Under physiological conditions, GDF-15 is essential...
(Senior) Research Associate - Immuno-Oncology (gn)
About us
iOmx Therapeutics is a clinical-stage company in the field of immuno-oncology located in Martinsried/Munich, Germany. We are focusing on the development of first-in-class cancer immunot...
